Dyadic Partners with Scripps for Hantavirus Antibody Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
Dyadic International Inc. is experiencing a pre-market decline of 6.45% as it crosses below its 5-day SMA.
The company has announced a collaboration with Scripps Research to develop monoclonal antibodies targeting hantaviruses, which are crucial for enhancing responses to severe respiratory diseases. This partnership reflects Dyadic's strategic focus on the biopharmaceutical sector and its commitment to addressing infectious disease threats through its advanced C1 platform, which has shown high efficiency in producing biologics.
This collaboration not only positions Dyadic favorably in the biopharmaceutical landscape but also underscores the potential of its C1 platform in rapidly developing effective treatments, which could be vital in future health crises.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DYAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DYAI
About DYAI
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dyadic Partners with Scripps to Develop Monoclonal Antibodies Against Hantaviruses
- Antibody Development Collaboration: Dyadic is collaborating with Scripps Research to evaluate monoclonal antibodies and vaccine candidates targeting hantaviruses, aiming to enhance responses to severe respiratory diseases like HPS, reflecting the company's strategic positioning in the biopharmaceutical sector.
- Platform Advantages: Dyadic's C1 platform demonstrates high microbial fermentation efficiency across various biologics, capable of producing monoclonal antibodies with characteristics comparable to traditional mammalian systems within rapid development timelines, showcasing its potential in addressing future infectious disease threats.
- Funding and Partnerships: Dyadic is currently involved in multiple funded biopharmaceutical collaborations, including partnerships with the Gates Foundation and CEPI, aimed at accelerating recombinant protein vaccines and monoclonal antibody development, further validating the commercial potential of the C1 platform.
- Pandemic Response Challenges: The C1 platform's importance in manufacturing flexibility and speed was highlighted during the COVID-19 pandemic, and Dyadic plans to continue advancing rapid biologic production through strategic collaborations and funded research to tackle emerging infectious disease challenges.
See More
Dyadic International to Present at Investor Conference
- Conference Details: Joe Hazelton, President and COO of Dyadic International, is scheduled to present at Sidoti's Virtual Investor Conference on May 20, 2026, at 10:00 AM ET, aiming to showcase the company's latest developments and strategic direction to attract potential investors and bolster market confidence.
- One-on-One Meetings: Management will host virtual one-on-one meetings during the conference, allowing investors to register and gain deeper insights into Dyadic's business model and future plans, which enhances investor relations and transparency.
- Technological Edge: Dyadic Applied BioSolutions leverages its proprietary microbial platforms to produce recombinant proteins that are widely used across life sciences, food and nutrition, and bio-industrial markets, aiming to help customers develop more efficient, scalable, and sustainable products, thereby enhancing market competitiveness.
- Risk Factors: The statement highlights various forward-looking statements, emphasizing risks faced by Dyadic, including market acceptance, potential failure to commercialize technologies, and capital needs, which could impact the company's future financial performance and strategic execution.
See More
Dyadic International Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: In Q1 2026, Dyadic International reported total revenue of approximately $1.1 million, representing a 182% increase year-over-year, primarily driven by higher research and development revenue, ongoing grant revenues, and milestone revenue, indicating strong momentum in its commercialization efforts.
- Product Commercialization Progress: The company marked successful commercialization of its microbial production platform through partnerships with Proliant Health for the launch of Albufree Dx recombinant human albumin and Inzymes for recombinant non-animal bovine chymosin, attracting increasing interest from potential partners and customers.
- Cash Flow and Expense Management: As of the end of Q1 2026, Dyadic International had approximately $6.6 million in cash and cash equivalents, with expectations that these funds will support operations into Q2 2027 while maintaining operating expenses in line with 2025 levels, ensuring financial stability.
- Optimistic Future Outlook: Management anticipates continued growth in product revenues throughout 2026, supported by recent product launches and increased customer engagement, emphasizing a focus on building recurring revenue opportunities while maintaining disciplined cash management.
See More
Dyadic International Reports Q1 2026 Financial Highlights
- Significant Revenue Growth: Dyadic International reported Q1 2026 revenue of $1.1 million, representing a substantial 182% increase year-over-year, primarily driven by higher R&D revenue, grant funding, and milestone payments, thereby solidifying the company's transition to a commercial biotechnology firm.
- Strategic Transition Progress: The company is advancing its shift from a platform technology provider to a commercial biotechnology entity, launching recombinant proteins and enzymes that have attracted interest from potential partners, which is expected to diversify future revenue streams.
- Partnership Expansion: Collaborations with Proliant Health Biologicals and Enzymes have led to the commercial launch of recombinant human albumin and non-animal enzymes, marking significant progress in the commercialization of the company's technology and further validating its production platform's market potential.
- Robust Cash Management: The company anticipates that its existing resources will sustain operations into Q2 2027, emphasizing a disciplined cash management strategy while expanding product sales and partnerships to ensure long-term growth.
See More
Dyadic International Reports FY 2025 Earnings Results
- Earnings Performance: Dyadic International reported a FY 2025 GAAP EPS of -$0.23, aligning with market expectations, indicating ongoing challenges in profitability.
- Revenue Decline: The company's revenue for FY 2025 was $3.09 million, representing an 11.7% year-over-year decrease and missing market expectations by $0.77 million, reflecting a lack of sales growth.
- Cash Flow Status: As of December 31, 2025, Dyadic's total cash, cash equivalents, restricted cash, and investment-grade securities amounted to $8.6 million, down from $9.29 million in 2024, highlighting increased liquidity pressure.
- Future Outlook: Dyadic aims to achieve product revenue growth and commercialization milestones in 2026 while expanding partnerships, intending to improve future financial performance and market competitiveness.
See More
Dyadic International Q4 2025 Earnings Call Insights
- Accelerated Commercialization: Since assuming the role of President in June 2025, Joseph Hazelton emphasized that the company has rapidly transitioned from a development stage to a commercial product-driven biotechnology firm, indicating multiple paths for revenue diversification are forming.
- Revenue Growth Potential: Total revenue for 2025 was $3.09 million, a decrease from $3.5 million in 2024; however, the increase of $1.86 million in grant revenue from the Gates Foundation and CEPI demonstrates the company's diversification in funding sources.
- Product Launches and Collaborations: The commercial collaboration with Proliant Health & Biologicals for recombinant albumin marks the launch of the first platform-enabled product, expected to generate recurring revenue, while the agreement with BRIG BIO will enhance market penetration for animal-free recombinant products.
- Future Outlook: Management anticipates revenue growth in product sales for 2026, emphasizing disciplined cash usage and prioritization of high-impact R&D projects to support ongoing growth in life sciences and food and nutrition markets.
See More
Dyadic Partners with Scripps to Develop Monoclonal Antibodies Against Hantaviruses
- Antibody Development Collaboration: Dyadic is collaborating with Scripps Research to evaluate monoclonal antibodies and vaccine candidates targeting hantaviruses, aiming to enhance responses to severe respiratory diseases like HPS, reflecting the company's strategic positioning in the biopharmaceutical sector.
- Platform Advantages: Dyadic's C1 platform demonstrates high microbial fermentation efficiency across various biologics, capable of producing monoclonal antibodies with characteristics comparable to traditional mammalian systems within rapid development timelines, showcasing its potential in addressing future infectious disease threats.
- Funding and Partnerships: Dyadic is currently involved in multiple funded biopharmaceutical collaborations, including partnerships with the Gates Foundation and CEPI, aimed at accelerating recombinant protein vaccines and monoclonal antibody development, further validating the commercial potential of the C1 platform.
- Pandemic Response Challenges: The C1 platform's importance in manufacturing flexibility and speed was highlighted during the COVID-19 pandemic, and Dyadic plans to continue advancing rapid biologic production through strategic collaborations and funded research to tackle emerging infectious disease challenges.
See More
Dyadic International to Present at Investor Conference
- Conference Details: Joe Hazelton, President and COO of Dyadic International, is scheduled to present at Sidoti's Virtual Investor Conference on May 20, 2026, at 10:00 AM ET, aiming to showcase the company's latest developments and strategic direction to attract potential investors and bolster market confidence.
- One-on-One Meetings: Management will host virtual one-on-one meetings during the conference, allowing investors to register and gain deeper insights into Dyadic's business model and future plans, which enhances investor relations and transparency.
- Technological Edge: Dyadic Applied BioSolutions leverages its proprietary microbial platforms to produce recombinant proteins that are widely used across life sciences, food and nutrition, and bio-industrial markets, aiming to help customers develop more efficient, scalable, and sustainable products, thereby enhancing market competitiveness.
- Risk Factors: The statement highlights various forward-looking statements, emphasizing risks faced by Dyadic, including market acceptance, potential failure to commercialize technologies, and capital needs, which could impact the company's future financial performance and strategic execution.
See More
Dyadic International Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: In Q1 2026, Dyadic International reported total revenue of approximately $1.1 million, representing a 182% increase year-over-year, primarily driven by higher research and development revenue, ongoing grant revenues, and milestone revenue, indicating strong momentum in its commercialization efforts.
- Product Commercialization Progress: The company marked successful commercialization of its microbial production platform through partnerships with Proliant Health for the launch of Albufree Dx recombinant human albumin and Inzymes for recombinant non-animal bovine chymosin, attracting increasing interest from potential partners and customers.
- Cash Flow and Expense Management: As of the end of Q1 2026, Dyadic International had approximately $6.6 million in cash and cash equivalents, with expectations that these funds will support operations into Q2 2027 while maintaining operating expenses in line with 2025 levels, ensuring financial stability.
- Optimistic Future Outlook: Management anticipates continued growth in product revenues throughout 2026, supported by recent product launches and increased customer engagement, emphasizing a focus on building recurring revenue opportunities while maintaining disciplined cash management.
See More
Dyadic International Reports Q1 2026 Financial Highlights
- Significant Revenue Growth: Dyadic International reported Q1 2026 revenue of $1.1 million, representing a substantial 182% increase year-over-year, primarily driven by higher R&D revenue, grant funding, and milestone payments, thereby solidifying the company's transition to a commercial biotechnology firm.
- Strategic Transition Progress: The company is advancing its shift from a platform technology provider to a commercial biotechnology entity, launching recombinant proteins and enzymes that have attracted interest from potential partners, which is expected to diversify future revenue streams.
- Partnership Expansion: Collaborations with Proliant Health Biologicals and Enzymes have led to the commercial launch of recombinant human albumin and non-animal enzymes, marking significant progress in the commercialization of the company's technology and further validating its production platform's market potential.
- Robust Cash Management: The company anticipates that its existing resources will sustain operations into Q2 2027, emphasizing a disciplined cash management strategy while expanding product sales and partnerships to ensure long-term growth.
See More
Dyadic International Reports FY 2025 Earnings Results
- Earnings Performance: Dyadic International reported a FY 2025 GAAP EPS of -$0.23, aligning with market expectations, indicating ongoing challenges in profitability.
- Revenue Decline: The company's revenue for FY 2025 was $3.09 million, representing an 11.7% year-over-year decrease and missing market expectations by $0.77 million, reflecting a lack of sales growth.
- Cash Flow Status: As of December 31, 2025, Dyadic's total cash, cash equivalents, restricted cash, and investment-grade securities amounted to $8.6 million, down from $9.29 million in 2024, highlighting increased liquidity pressure.
- Future Outlook: Dyadic aims to achieve product revenue growth and commercialization milestones in 2026 while expanding partnerships, intending to improve future financial performance and market competitiveness.
See More
Dyadic International Q4 2025 Earnings Call Insights
- Accelerated Commercialization: Since assuming the role of President in June 2025, Joseph Hazelton emphasized that the company has rapidly transitioned from a development stage to a commercial product-driven biotechnology firm, indicating multiple paths for revenue diversification are forming.
- Revenue Growth Potential: Total revenue for 2025 was $3.09 million, a decrease from $3.5 million in 2024; however, the increase of $1.86 million in grant revenue from the Gates Foundation and CEPI demonstrates the company's diversification in funding sources.
- Product Launches and Collaborations: The commercial collaboration with Proliant Health & Biologicals for recombinant albumin marks the launch of the first platform-enabled product, expected to generate recurring revenue, while the agreement with BRIG BIO will enhance market penetration for animal-free recombinant products.
- Future Outlook: Management anticipates revenue growth in product sales for 2026, emphasizing disciplined cash usage and prioritization of high-impact R&D projects to support ongoing growth in life sciences and food and nutrition markets.
See More
